Previous 10 | Next 10 |
SAN FRANCISCO , Feb. 7, 2019 /PRNewswire/ -- The largest study to date on the genetics of prostate cancer has found that 17 percent of prostate cancer patients are born with genetic variants that can be associated with higher risk of various cancers. The study was published today in ...
SAN FRANCISCO , Jan. 29, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, today announced that it will report its fourth quarter and year-end 2018 financial results on Tuesday, February 19, 2019 and will host a conference call ...
“I think the biggest innovations of the 21st century will be the intersection of biology and technology. A new era is beginning. Steve Jobs, as quoted in Steve Jobs by Walter Isaacson In 2003 the Human Genome Project succeeded at fully sequencing and mapping the genetic code of ...
Written by Ophir Gottlieb Preface We added Invitae (NVTA) to Top Picks for $7.42 on Sept. 1, 2016. As of this writing, the stock is trading at $13.82, up 86%. While we recently updated Number 1 Spotlight Top Pick Invitae with an earnings pre-announcement , today, at the JP Morgan co...
Invitae (NYSE: NVTA ) jumps 2.3% in premarket trading after issuing 2019 revenue guidance that exceeds the high end of analysts' estimates. More news on: Invitae, Healthcare stocks news, Stocks on the move, Read more ...
SAN FRANCISCO , Jan. 7, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, announced preliminary unaudited full-year 2018 results showing triple-digit growth driven by strong commercial execution, test menu expansion and the acc...
SAN FRANCISCO , Dec. 20, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George , co-founder and chief executive officer of Invitae, will present at the 37th Annual J.P. Morgan Healthcare Conference on W...
SAN FRANCISCO , Dec. 10, 2018 /PRNewswire/ -- Current guidelines for genetic testing of breast cancer patients miss as many patients with pathogenic variants (or genetic mutations) as they find, according to a new study published in the Journal of Clinical Oncology by researchers fro...
NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of United Technologies Corporation (NYSE:UTX), Walmart Inc. (NYSE:WMT), I...
Providers of molecular diagnostic testing services may see some action today on the heels of the FDA's approval for Loxo Oncology's VITRAKVI (larotrectinib) since it is the first cancer drug that will require prospective patients to have their DNA sequenced. More news on: Biocept, Inc., My...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...